Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Blood (2025) 146 (Supplement 1): 1841.

https://doi.org/10.1182/blood-2025-1841

Published: 2025

Journal Articles

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers

Blood (2025) 146 (Supplement 1): 4514.

https://doi.org/10.1182/blood-2025-4514

Published: 2025

Journal Articles

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2025-4499

Published: 2025

Journal Articles

Multiomic correlates of ex vivo αCD19 chimeric antigen receptor T-cell (CART) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL)

Jacob Wright, Francisco Hernandez-Ilizaliturri, Cory Mavis, Joseph Tario, Alex Niu, Taylor Mandeville, Dorothy Pan, Grant Schofield, Dae-Kyum Kim, Joseph Barbi, Hua-Hsin Hsiao, Spencer Rosario, Matthew Cortese

Blood (2025) 146 (Supplement 1): 5661.

https://doi.org/10.1182/blood-2025-5661

Published: 2025

Journal Articles

Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola R+CHP) results in similar clinical outcomes than rituximab and dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R+DA-EPOCH) in patients with high-risk features diffuse large B-cell lymphoma (DLBCL): A single institution experience.

Rahul Thakur, Han Yu, Mariam Haji, Vaishali Deenadayalan, Vasanthan Kumarasamy, Ajinkya Buradkar, Jordan Scott, Grant Schofield, Dorothy Pan, Matthew Cortese, Francisco Hernandez-Ilizaliturri, Alex Niu

Blood (2025) 146 (Supplement 1): 3685.

https://doi.org/10.1182/blood-2025-3685

Published: 2025

Journal Articles

Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Aung Tun, Romil Patel, Frederique St-Pierre, Evguenia Bhurtel, Alex Niu, Thorunn Thordardottir, Jennifer Obasi, Allison Rosenthal, Priyanka Pophali, Timothy Fenske, Reem Karmali, Patrick Johnston, Sairah Ahmed

Blood (2025) 146 (Supplement 1): 6310.

https://doi.org/10.1182/blood-2025-6310

Published: 2025

Journal Articles

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 402.

https://doi.org/10.1182/blood-2025-402

Published: 2025

Journal Articles

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

Blood (2025) 146 (Supplement 1): 401.

https://doi.org/10.1182/blood-2025-401

Published: 2025

Journal Articles

IL-2 mutein-mediated improvement of CAR T function in Relapsed/Refractory diffuse B cell lymphoma

Allan Pavy, Cooper Sailer, Shannon McSain, Tania Carmenate, Kalet Leon, Alex Niu, Meredith Stone, Circe Mesa, Marco Davila

Blood (2025) 146 (Supplement 1): 5880.

https://doi.org/10.1182/blood-2025-5880

Published: 2025

Journal Articles

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Blood (2025) 146 (Supplement 1): 3622.

https://doi.org/10.1182/blood-2025-3622

Published: 2025

Journal Articles

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Blood (2025) 146 (18): 2177–2188.

https://doi.org/10.1182/blood.2025029117

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2024-199278

Published: 2024

Journal Articles

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Blood (2024) 144 (Supplement 1): 525.

https://doi.org/10.1182/blood-2024-212106

Published: 2024

Journal Articles

Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment

Matthew J. Cortese, MD, MPH, Jacob P Wright, Cory Mavis, Taylor K Mandeville, Alex Niu, Dae-Kyum Kim, Spencer Rosario, Francisco Hernandez-Ilizaliturri

Blood (2024) 144 (Supplement 1): 78.

https://doi.org/10.1182/blood-2024-212019

Published: 2024

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Blood (2023) 142 (Supplement 1): 103.

https://doi.org/10.1182/blood-2023-175034

Published: 2023

Journal Articles

Chimeric Antigen Receptor T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multicenter Study

Aung M. Tun, Romil Patel, Frederique St-Pierre, Evguenia Ouchveridze, Alex Niu, Jennifer Obasi, Allison C. Rosenthal, Priyanka A Pophali, Timothy S. Fenske, Reem Karmali, Sairah Ahmed, Patrick B Johnston

Blood (2023) 142 (Supplement 1): 311.

https://doi.org/10.1182/blood-2023-179509

Published: 2023

Journal Articles

COVID-19 Immune Response in Hematologic Malignancies: Analysis of COVID-19 Anti-Spike Antibodies in Previously Infected and Uninfected Patients

Alex Niu, Victor H Ramirez, Bronwyn Gunn, Melyssa Bratton, Sarah Foster, James Robinson, Sree Lanka, Hana Safah, Francisco Socola, Yunwen Huang, Crystal Y Zheng, Ivy V Trinh, Amelie E Murrell, Jeffrey G Shaffer, Elizabeth B Norton, Nakhle S. Saba

Blood (2022) 140 (Supplement 1): 8351–8353.

https://doi.org/10.1182/blood-2022-165019

Published: 2022

Journal Articles

COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141578

Published: 2020

Journal Articles

COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality

Alex Niu, MD, Bo Ning, PhD, Francisco Socola, MD, Hana Safah, MD, Tim Reynolds, Moayed Ibrahim, MD, Firas Safa, MD, Tina Alfonso, Alfred Luk, MD, David M Mushatt, MD, Tony Hu, PhD, Nakhle S. Saba, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-138611

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Multiomic correlates of ex vivo αCD19 chimeric antigen receptor T-cell (CART) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL)

Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

IL-2 mutein-mediated improvement of CAR T function in Relapsed/Refractory diffuse B cell lymphoma

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Chimeric Antigen Receptor T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multicenter Study

COVID-19 Immune Response in Hematologic Malignancies: Analysis of COVID-19 Anti-Spike Antibodies in Previously Infected and Uninfected Patients

COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients

COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only